Cargando…
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/ https://www.ncbi.nlm.nih.gov/pubmed/33015549 http://dx.doi.org/10.1007/s42399-020-00550-3 |